Journal of Integrative Natural Science (통합자연과학논문집)

The Basic Science Institute Chosun University (조선대학교 기초과학연구원)
권호 표지
DOI QR코드

DOI QR Code

Hologram Based QSAR Analysis of CXCR-2 Inhibitors

  • Sathya., B (Department of Bioinformatics, School of Bioengineering, SRM University)
  • Received : 2017.05.08
  • Accepted : 2017.06.25
  • Published : 2017.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

CXC chemokine receptor 2 (CXCR2) is a prominent chemokine receptor on neutrophils. CXCR2 antagonist may reduce the neutrophil chemotaxis and alter the inflammatory response because the neutrophilic inflammation in the lung diseases is found to be largely regulated through CXCR2 receptor. Hence, in the present study, Hologram based Quantitative Structure Activity Relationship Study was performed on a series of CXCR2 antagonist named pyrimidine-5-carbonitrile-6-alkyl derivatives. The best HQSAR model was obtained using atoms, bonds, and chirality as fragment distinction parameter using hologram length 151 and 6 components with fragment size of minimum 4 and maximum 7. Significant cross-validated correlation coefficient ($q^2=0.774$) and non cross-validated correlation coefficients ($r^2=0.977$) were obtained. The model was then used to evaluate the six external test compounds and its $r^2_{pred}$ was found to be 0.614. Contribution map show that presence of cyclopropyl ring and its bulkier substituent's makes big contributions for improving the biological activities of the compounds. We hope that our HQSAR model and analysis will be helpful for future design of novel and structurally related CXCR2 antagonists.

Keywords

References

  1. M. Uguccioni, M. D'Apuzzo, M. Loetscher, B. Dewald, and M. Baggiolini, "Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes", Eur. J. Immunol., Vol. 25, pp. 64-68, 1995. https://doi.org/10.1002/eji.1830250113
  2. R. W. Chapman, J. E. Phillips, R. W. Hipkin, A. K. Curran, D. Lundell, and J. S. Fine, "CXCR2 antagonists for the treatment of pulmonary disease", Pharmacol. Ther., Vol. 121, pp. 55-68, 2009. https://doi.org/10.1016/j.pharmthera.2008.10.005
  3. K. J. Eash, A. M. Greenbaum, P. K. Gopalan, and D. C. Link, "CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow", J. Clin. Invest., Vol. 120, pp. 2423-2431, 2010. https://doi.org/10.1172/JCI41649
  4. J. Reutershan, A. Basit, E. V. Galkina, and K. Ley, "Sequential recruitment of neutrophils into lung and bronchoalveolar lavage fluid in LPS-induced lung injury", Am. J. Physiol. Lung Cell. Mol. Physiol., Vol. 289, pp. L807-L815, 2005. https://doi.org/10.1152/ajplung.00477.2004
  5. S. L. Traves, S. J. Smith, P. J. Barnes, and L. E. Donnelly, "Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2", J. Leukoc. Biol., Vol. 76, pp. 441-450, 2004. https://doi.org/10.1189/jlb.1003495
  6. R. A. Pauwels and K. F. Rabe, "Burden and clinical features of chronic obstructive pulmonary disease (COPD)", Lancet, Vol. 364, pp. 613-620, 2004. https://doi.org/10.1016/S0140-6736(04)16855-4
  7. E. H. Bel, A. Sousa, L. Fleming, A. Bush, K. F Chung, J. Versnel, A. H. Wagener, S. S. Wagers, P. J. Sterk, and C. H. Compton, "Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI)", Thorax, Vol. 66, pp. 910-917, 2011. https://doi.org/10.1136/thx.2010.153643
  8. P. Anderson, "Emerging therapies in cystic fibrosis", Ther. Adv. Respir. Dis., Vol. 4, pp. 177-185, 2010. https://doi.org/10.1177/1753465810371107
  9. P. M. Murphy, "Neutrophil receptors for interleukin-8 and related CXC chemokines", Semin. Hematol., Vol. 34, pp. 311-318, 1997.
  10. T. Puzyn, J. Lesczynski, and M. T. Cronin, "Recent advances in QSAR Studies" in Challenges and Advances in Computational Chemistry and Physics, Vol. 8, Germany: Springer, pp. 103-125, 2010.
  11. Tripos Sybyl, HQSAR manual.
  12. C. L. Waller, "A comparative QSAR study using CoMFA, HQSAR, and FRED/SKEYS paradigms for estrogen receptor binding affinities of structurally diverse compounds", J. Chem. Inf. Model., Vol. 44, pp. 758-765, 2004.
  13. W. Tong, D. R. Lowis, R. Perkins, Y. Chen, W. J. Welsh, D. W. Goddette, T. W. Heritage, and D. M. Sheehan, "Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor", J. Chem. Inf. Model., Vol. 38, pp. 669-677, 1998.
  14. T. W Heritage and D. R. Lowis, "Molecular hologram QSAR", In Rational Drug design: Novel methodology and Practical Applications, eds. A. L. Parrill, M. R. Reddy, Washington: American Chemical Society, Symposium Series, Vol. 719, pp. 212-225, 1999.
  15. D. W. Porter , M. Bradley, Z. Brown, S. J. Charlton, B. Cox, P. Hunt, D. Janus, S. Lewis, P. Oakley, D. O'Connor, J. Reilly, N. Smith, and N. J. Press, "The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists", Bioorg. Med. Chem. Lett., Vol. 24, pp. 3285-3290, 2014. https://doi.org/10.1016/j.bmcl.2014.06.011
  16. D. A Winker and F. R. Burden, "Holographic QSAR of benzodiazepines", Mol. Inform., Vol. 17, pp. 224-231, 1998.
  17. S. Wold, "Cross-validatory estimation of the number of components in factor and principal component model", Technometrics, Vol. 20, pp. 397-405, 1978. https://doi.org/10.1080/00401706.1978.10489693